A Study of Irinotecan Hydrochloride Liposome in Advanced Solid Tumors
Status:
Completed
Trial end date:
2017-08-28
Target enrollment:
Participant gender:
Summary
This is an open label, dose-escalation and expansion, single centre, phase Ia study . In this
study, the tolerability, safety, pharmacokinetics and efficacy of irinotecan hydrochloride
liposome injection were studied in patients with advanced solid tumors, to determine the
dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of irinotecan hydrochloride
liposome.